CCO Treatment Updates
Simple From the Start: The Importance of Treatment Convenience in Antiretroviral Therapy
Recent Advances in Simplifying Antiretroviral Therapy |
Module 1 of 2 |
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, discusses key advances toward simpler antiretroviral treatments and their clinical use in antiretroviral-naive patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the key developments in the evolution of antiretroviral therapy and their role in treatment simplification
- Discuss the significance of pill burden and dosing frequency for patient adherence to antiretroviral therapy
- Identify factors that can influence a patient’s ability to adhere to an antiretroviral regimen
- Discuss the differences between antiretroviral regimens as they relate to treatment simplicity and convenience
|
Clinical Significance of Simplicity and Adherence in Antiretroviral Therapy |
Module 2 of 2 |
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, discusses key advances toward simpler antiretroviral treatments and their clinical use in antiretroviral-naive patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the significance of pill burden and dosing frequency for patient adherence to antiretroviral therapy
- Identify factors that can influence a patient’s ability to adhere to an antiretroviral regimen
- Discuss the relationship between adherence and clinical response to antiretroviral therapy
- Discuss the differences between antiretroviral regimens as they relate to treatment simplicity and convenience
|
Interactive Case Challenges
Selection of Initial Therapy for a 48-Year-Old HIV/TB-Coinfected Woman With Cardiovascular Disease Risk Factors
- Anton L. Pozniak, MD, FRCP
|
|
|
Anton L. Pozniak, MD, FRCP, discusses key considerations in choosing an initial antiretroviral regimen for a 48-year-old woman coinfected with HIV and TB.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the significance of simplified antiretroviral regimens in supporting patient adherence
- Discuss factors to be considered when designing antiretroviral regimens for treatment-naive patients with comorbid conditions requiring concomitant treatment
- Describe considerations in designing antiretroviral treatments to limit the risk of lipoatrophy
- Identify appropriate strategies for the treatment of patients who are coinfected with HIV and tuberculosis
|
Management of a 38-Year-Old Male on Methadone Maintenance Therapy Who Presents With PCP
|
|
|
William G. Powderly, MD, discusses selection of initial therapy for a 38-year-old recovering IDU male with HIV/HCV coinfection who presents with PCP.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss key factors to be considered in treating an antiretroviral-naive patient who presents with an acute opportunistic infection
- Discuss key considerations in selecting an initial antiretroviral regimen for a patient with advanced HIV disease
- Describe the significance of resistance mutations in a chronically HIV-infected patient
- Identify key considerations in selecting an initial antiretroviral regimen for a patient on methadone maintenance therapy
|
Management of a 38-Year-Old Otherwise Healthy Married Man Recently Diagnosed With HIV Infection
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, discusses key concerns about the initiation of antiretroviral therapy for a 38-year-old busy professional man recently diagnosed with HIV.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the significance of pill burden and dosing frequency for patient adherence to antiretroviral therapy
- Identify factors that can influence a patient’s ability to adhere to an antiretroviral regimen
- Describe strategies to prevent HIV transmission that are applicable to persons newly diagnosed with HIV infection
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|